
LVTX Stock Forecast & Price Target
LVTX Analyst Ratings
Bulls say
LAVA Therapeutics NV is advancing its clinical-stage immuno-oncology platform focused on bispecific antibody development, which may revolutionize cancer treatment. The company recently announced a definitive agreement to acquire XOMA Royalty, a strategic move that underscores LAVA's commitment to enhancing its pipeline and financial positioning. This acquisition, alongside promising developments from its pipeline including LAVA-1266 and LAVA-1427, suggests strong future potential for the company's growth and value creation.
Bears say
LAVA Therapeutics NV has announced the discontinuation of its Phase 1 study of LAVA-1266, indicating a significant setback in its clinical development pipeline. The company's ongoing plans to wind down this program come amid a pending acquisition, raising concerns about its financial stability and future growth prospects. This situation has prompted a reevaluation of the company's valuation, resulting in a lowered price target, which reflects an overall negative outlook for LAVA's stock performance.
This aggregate rating is based on analysts' research of LAVA Therapeutics NV and is not a guaranteed prediction by Public.com or investment advice.
LVTX Analyst Forecast & Price Prediction
Start investing in LVTX
Order type
Buy in
Order amount
Est. shares
0 shares